Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
AEON Biopharma Reports Inducement Grants Under NYSE American LLC Company Guide Section 711
-
Psyence BioMed Announces Approval for Use of PsyLabs’ Psilocybin Product in Phase IIb Clinical Trial
NEW YORK, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine...
-
Annovis will begin Open-Label Extension study in Parkinson's disease patients
-
SYDNEY, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Actinogen Medical Limited (ASX: ACW) announces that due to the recent accelerated screening and enrolment in the XanaMIA phase 2b/3 Alzheimer’s disease (AD)...
-
OV350 showed a good safety profile, supporting the advancement of the Company’s KCC2 portfolio, including the first oral direct activator, OV4071There were no treatment-related laboratory findings, no...
-
Quanta LOI
-
Numab to receive milestone payment Boehringer Ingelheim has advanced its novel multi-specific antibody for retinal diseases resulting from a collaboration with Numab into preclinical development ...
-
Plano, Texas, Dec. 17, 2025 (GLOBE NEWSWIRE) -- As 2025 comes to a close, BioNTX reflects on a year of innovation, growth, and achievement across North Texas’ life science ecosystem, highlighted by...
-
VANCOUVER, British Columbia, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO0) (“Rakovina” or the “Company”), a biopharmaceutical company advancing innovative...
-
BBOT today announced that members of its leadership team will participate in a presentation at the 44th Annual J.P. Morgan Healthcare Conference.